|Bid||3.805 x 100000|
|Ask||3.830 x 100000|
|Day's Range||3.805 - 3.805|
|52 Week Range||3.515 - 7.421|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.35|
BERLIN, and GERMANTOWN, Md. , Aug. 30, 2017 /PRNewswire/ -- Epigenomics AG (Frankfurt Prime Standard: ECX) (OTCQX: EPGNY), today announced the initiation of a Post Approval Study (PAS), Performance of ...
VNRX is required to contribute just $3M (paid in equal quarterly installments over 3 years), with most of the funding borne by the study's main sponsor, the U.S. National Cancer Institute's (NCI) Early Detection Network (EDRN), which is the leading cancer research organization in the U.S. The Great Lakes New England Clinical Validation Center and the University of Michigan are also major participants and, along with EDRN, focused on the pursuit of technologies for the early detection of cancer. • will include ~13.5k asymptomatic screening samples from subjects 50 years of age who have not previously undergone colonoscopy or CRC screening.